Comparison of clinical outcomes of treatment with cefepime monotherapy vs. amikacin-ceftriaxone combination in children with chemotherapy-induced fever and neutropenia

Ghelichkhan, Zahra; Mohsenzadeh, Sarah; Noroozi, Mehran; Ghazizadeh, Farid

doi:10.61186/rabms.11.2.227

Volume 11, Issue 2 (4-2025) Journal of Research in Applied and Basic Medical Sciences 2025, 11(2): 227-234 | Back to browse issues page

‎ 10.61186/rabms.11.2.227

Ethics code: IR.UMSU.REC.1400.245

Mendeley

Zotero

RefWorks

Ghelichkhan Z, Mohsenzadeh S, Noroozi M, Ghazizadeh F. Comparison of clinical outcomes of treatment with cefepime monotherapy vs. amikacin-ceftriaxone combination in children with chemotherapy-induced fever and neutropenia. Journal of Research in Applied and Basic Medical Sciences 2025; 11 (2) :227-234
URL: http://ijrabms.umsu.ac.ir/article-1-302-en.html

Comparison of clinical outcomes of treatment with cefepime monotherapy vs. amikacin-ceftriaxone combination in children with chemotherapy-induced fever and neutropenia

Zahra Ghelichkhan ^*

, Sarah Mohsenzadeh

, Mehran Noroozi

, Farid Ghazizadeh

Department of Clinical Pharmacy, School of Pharmacy, Urmia University of Medical SciencesUrmia University of Medical Sciences , gkhan.z@umsu.ac.ir

Abstract: (187 Views)

Background & Aims: Fever and neutropenia are major causes of mortality in cancer patients. This study compares the effectiveness of cefepime monotherapy with a ceftriaxone–amikacin combination in treating these complications.
Materials & Methods: In a randomized clinical trial, 60 febrile neutropenic children with cancer at Shahid Motahari Hospital, Urmia, were assigned to receive either cefepime monotherapy or ceftriaxone–amikacin combination therapy. The hospital length of stay, time to defervescence, and frequency of therapy escalation were compared between the two groups.
Results: The cefepime group had a shorter hospital stay, fewer febrile episodes, reduced antipyretic use, and less frequent antimicrobial escalation compared to the combination group. No significant differences were observed in laboratory results between admission and discharge in either group.
Conclusion: Cefepime monotherapy was significantly more effective than ceftriaxone–amikacin combination therapy in managing fever and neutropenia in pediatric cancer patients.

Keywords: Amikacin, Cefepime, Ceftriaxone, Amikacin, Fever, Neutropenia, Pediatric

Full-Text [PDF 476 kb] (50 Downloads)

Type of Study: orginal article | Subject: Other

References

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Cancer 2004;100(2):228-37. [DOI:10.1002/cncr.11882] [PMID]

2. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017;35(18):2082-94. [DOI:10.1200/JCO.2016.71.7017] [PMID]

3. Prevention and Treatment of Cancer-Related Infections [Internet]. [cited 2025 Jun 4]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf [URL]

4. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical practice guideline update. J Clin Oncol 2018;36(14):1443-53. [DOI:10.1200/JCO.2017.77.6211] [PMID]

5. Anoop P, Patil CN. Management of Febrile Neutropenia in Children: Current Approach and Challenges. Pediatr Infect Dis 2020;2(4):136. [DOI:10.5005/jp-journals-10081-1257]

6. Mohammed HB, Yismaw MB, Fentie AM, Tadesse TA. Febrile neutropenia management in pediatric cancer patients at Ethiopian Tertiary Care Teaching Hospital. BMC Res Notes 2019;12:1-6. [DOI:10.1186/s13104-019-4569-5] [PMID] [PMCID]

7. Jungrungrueng T, Anugulruengkitt S, Lauhasurayotin S, Chiengthong K, Poparn H, Sosothikul D, et al. The pattern of microorganisms and drug susceptibility in pediatric oncologic patients with febrile neutropenia. J Pathog 2021;2021:6692827. [DOI:10.1155/2021/6692827] [PMID] [PMCID]

8. Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract 2019;15(1):19-24. [DOI:10.1200/JOP.18.00269] [PMID]

9. Lehrnbecher T, Robinson PD, Ammann RA, Fisher B, Patel P, Phillips R, et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients with Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update. J Clin Oncol 2023;41(9):1774-85. [DOI:10.1200/JCO.22.02224] [PMID] [PMCID]

10. Cometta A, Calandra T, Gaya H, Zinner SH, De Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40(5):1108-15. [DOI:10.1128/AAC.40.5.1108] [PMID] [PMCID]

11. Paul M, Leibovici L. Systematic reviews and meta-analysis of febrile neutropenia. Mayo Clin Proc 2005;80(9):1122-5. [DOI:10.4065/80.9.1122] [PMID]

12. Lal A, Bhurgri Y, Rizvi N, Virwani M, Memon RU, Saeed W, et al. Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev 2008;9(2):303-8. [Google Scholar]

13. Sealed Envelope Ltd. 2021. Create a blocked randomization list. [Internet]. [cited 2021 Sep 24]. Available from: https://www.sealedenvelope.com/simple-randomiser/v1/lists [URL]

14. Alam MM, Fadoo Z. Febrile neutropenia in pediatric cancer patients: Experience from a tertiary health care facility of Pakistan. Pediatr Infect Dis 2014;6(3):89-93. [DOI:10.1016/j.pid.2014.06.002]

15. Çorapçioǧlu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: A prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol 2005;22(1):59-70. [DOI:10.1080/08880010590896297] [PMID]

16. Davis K, Wilson S. Febrile neutropenia in paediatric oncology. Paediatr Child Health (Oxford) 2020;30(3):93-7. [DOI:10.1016/j.paed.2019.12.002] [PMID] [PMCID]

17. Mustafa MM, Carlson L, Tkaczewski I, MCCRACKEN JR GH, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001;20(3):362-9. [DOI:10.1097/00006454-200103000-00036] [PMID]